Rebus (RBSH) S-1 16 Dec 13 IPO registration Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013
Document Information [Line Items]	'
Entity Registrant Name	'GENSPERA INC
Entity Central Index Key	'0001421204
Entity Filer Category	'Smaller Reporting Company
Document Type	'S-1
Amendment Flag	'false
Document Period End Date	30-Sep-13

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
ASSETS	'	'	'
Cash and cash equivalents	$4,865	$2,345	$5,530
Prepaid expenses	195	77	0
Total current assets	5,060	2,422	5,530
Office equipment	16	12	9
Intangible assets	122	136	152
Other assets	3	3	0
Total assets	5,201	2,573	5,691
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'
Accounts payable	799	728	70
Accrued expenses	1,041	1,292	728
Warrant derivative - short-term	0	1,176	0
Convertible notes - stockholder	105	105	105
Total current liabilities	1,945	3,301	903
Warrant derivative - long-term	'	0	1,734
Total liabilities	1,945	3,301	2,637
Commitments and contingencies	'	'	'
Stockholders' equity (deficit):	'	'	'
Preferred stock	0	0	0
Common stock	3	2	2
Additional paid-in capital	33,582	26,353	23,215
Deficit accumulated during the development-stage	-30,329	-27,083	-20,163
Total stockholders' equity (deficit)	3,256	-728	3,054
Total liabilities and stockholders' equity	$5,201	$2,573	$5,691

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, except Share data, unless otherwise specified
Office equipment, accumulated depreciation (in dollars)	$15	$10	$7
Intangible assets, accumulated amortization (in dollars)	$90	$77	$60
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	30,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized	150,000,000	80,000,000	80,000,000
Common stock, shares issued	27,252,966	22,298,424	21,457,419
Common stock, shares outstanding	27,252,966	22,298,424	21,457,419

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		109 Months Ended	118 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013
Operating expenses:	'	'	'	'	'	'	'	'
General and administrative	$764	$894	$2,433	$2,473	$3,953	$3,262	$12,103	$14,536
Research and development	571	600	1,907	2,127	2,922	3,302	13,979	15,886
Research and development grant received	0	0	0	0	0	-244	-489	-489
Total operating expenses	1,335	1,494	4,340	4,600	6,875	6,320	25,593	29,933
Loss from operations	-1,335	-1,494	-4,340	-4,600	-6,875	-6,320	-25,593	-29,933
Finance cost	0	0	0	0	0	0	-519	-519
Gain (loss) on change in fair value of warrant derivative liability	330	-281	1,096	-1,029	-50	580	-1,010	86
Interest income (expense), net	0	1	-2	5	5	26	39	37
Loss before provision for income taxes	-1,005	-1,774	-3,246	-5,624	-6,920	-5,714	-27,083	-30,329
Provision for income taxes	0	0	0	0	0	0	0	0
Net loss	($1,005)	($1,774)	($3,246)	($5,624)	($6,920)	($5,714)	($27,083)	($30,329)
Net loss per common share, basic and diluted (in dollars per share)	($0.04)	($0.08)	($0.14)	($0.26)	($0.32)	($0.27)	'	'
Weighted average shares outstanding (in shares)	25,364,457	21,848,470	23,995,394	21,760,359	21,805,211	20,821,555	'	'

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERSb EQUITY (DEFICIT) (USD $)

Total

Common Stock

Additional Paid-in Capital

Common Stock Subscribed

Deficit Accumulated During Development Stage

Founders

Founders

Shares issued for services

Shares issued for services

Shares issued for services

Placement fees

Accrued Consulting Fees

Accrued Consulting Fees

Accrued Consulting Fees

Payment of consulting and placement fees

Payment of consulting and placement fees

Payment of consulting and placement fees

Warrants 1.65

Warrants 1.65

Warrants 1.65

Warrants 2.00

Warrants 2.00

Warrants 2.00

Warrants 1.80

Warrants 1.80

Warrants 1.80

Warrants 1.80

Warrants 1.50

Warrants 1.50

Warrants 1.50

In Thousands, except Share data

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

Common Stock

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

Common Stock Subscribed

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Nov. 20, 2003

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

1

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

120

'

120

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-125

'

'

'

-125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2003

-5

1

119

'

-125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2003

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

193

'

193

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24

'

24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-254

'

'

'

-254

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2004

-42

1

336

'

-379

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2004

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

48

'

48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24

'

24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-127

'

'

'

-127

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2005

-97

1

408

'

-506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2005

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

144

'

144

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

42

'

42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-245

'

'

'

-245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2006

-156

1

594

'

-751

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2006

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

650

'

650

'

'

'

'

367

'

367

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

1,300,000

'

'

'

'

'

'

735,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash

3

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

220

'

220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24

'

24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-691

'

'

'

-691

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2007

417

1

1,858

'

-1,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2007

'

9,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

2,320

'

2,320

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

2,320,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

50

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash

500

'

500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

50

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

314

'

314

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-206

'

-206

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for accrued interest

16

'

16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for accrued interest (in shares)

'

31,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature of convertible debt

20

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,326

'

'

'

-3,326

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2008

155

1

4,922

'

-4,768

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2008

'

12,486,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative effect of change in accounting principle

-734

'

-444

'

-290

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for extension of debt maturities

52

'

52

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

3,798

1

3,797

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

2,665,354

'

'

'

'

'

'

'

'

53,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

104

'

104

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

86,875

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,531

'

1,531

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued upon conversion of note and accrued interest

174

'

174

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued upon conversion of note and accrued interest (in shares)

'

174,165

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,134

'

'

'

-5,134

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2009

-54

2

10,136

'

-10,192

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2009

'

15,466,446

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

86

'

86

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

806

'

806

2,656

'

2,656

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

43,632

'

'

'

'

'

'

'

533,407

'

'

1,347,500

'

'

'

'

'

'

'

'

Stock-based compensation

1,165

'

1,165

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants subscribed

612

'

'

612

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued as payment for patents and license

47

'

47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued as payment for patents and license (in shares)

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries paid with common stock

100

'

100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries paid with common stock (in shares)

'

43,479

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

125

'

125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

150,001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-4,257

'

'

'

-4,257

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2010

1,286

2

15,121

612

-14,449

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2010

'

17,604,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

60

'

60

533

'

533

2,250

'

2,250

'

'

'

3,423

'

4,035

-612

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

61,498

'

33,334

'

'

152,895

'

'

1,363,622

'

'

'

'

'

2,241,605

'

'

'

'

'

Exercise of options for cash (in shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,290

'

1,290

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-74

'

-74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,714

'

'

'

-5,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

3,054

2

23,215

'

-20,163

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2011

'

21,457,419

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

608

'

608

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

652

'

652

'

'

'

'

'

'

'

'

'

'

'

674

'

674

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

296,366

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

513

'

513

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

691

'

691

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

544,639

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,920

'

'

'

-6,920

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

-728

2

26,353

'

-27,083

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2012

'

22,298,424

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

80

'

80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

1,217

'

1,217

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

1

4,999

Common stock and warrants issued (in shares)

'

757,794

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,333,356

'

Stock-based compensation

1,194

'

1,194

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

404

'

404

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

863,392

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-665

'

-665

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,246

'

'

'

-3,246

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Sep. 30, 2013

$3,256

$3

$33,582

'

($30,329)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Sep. 30, 2013

'

27,252,966

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENT_OF_STOCKHO1

CONDENSED STATEMENT OF STOCKHOLDERSb EQUITY (DEFICIT) (Parenthetical) (USD $)	9 Months Ended	12 Months Ended								9 Months Ended	1 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2013	Dec. 31, 2003
						Warrants 1.65	Warrants 1.65	Warrants 1.80	Warrants 2.00	Warrants 1.50	Founders
Sale of common stock, per share	'	'	'	'	$0.50	'	'	'	'	'	$0.00
Common stock and warrants issued, issuance date	'	'	'	'	'	'	'	'	'	'	'2003-11
Common stock and warrants issued, price per share	$1.77	$2.20	$1.50	$1	'	$1.65	$1.65	$1.80	$2	$1.50	'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		12 Months Ended		109 Months Ended	118 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'	'	'	'
Net loss	($3,246)	($5,624)	($6,920)	($5,714)	($27,083)	($30,329)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'	'	'
Depreciation and amortization	17	15	21	20	88	105
Stock-based compensation	1,194	365	513	1,823	6,081	7,275
Common stock issued for acquisition of license	0	0	0	0	29	29
Warrants issued for financing costs	0	0	0	0	468	468
Change in fair value of derivative liability	-1,096	1,029	50	-580	1,010	-86
Contributed services	0	0	0	0	774	774
Amortization of debt discount	0	0	0	0	21	21
Increase in operating assets:	'	'	'	'	'	'
Prepaid expenses	-118	0	-77	0	-77	-195
Other assets	0	0	-3	0	-3	-3
(Decrease) increase in operating liabilities:	'	'	'	'	'	'
Accounts payable and accrued expenses	-180	741	1,895	707	2,780	2,600
Cash used in operating activities	-3,429	-3,474	-4,521	-3,744	-15,912	-19,341
Cash flows from investing activities:	'	'	'	'	'	'
Acquisition of office equipment	-8	0	-7	0	-23	-31
Acquisition of intangibles	0	0	0	0	-194	-194
Cash used in investing activities	-8	0	-7	0	-217	-225
Cash flows from financing activities:	'	'	'	'	'	'
Proceeds from sale of common stock and warrants	6,217	0	652	5,673	17,627	23,844
Proceeds from exercise of options and warrants	405	494	691	0	816	1,221
Issuance cost of common stock and warrants sold	-665	0	0	-70	-74	-739
Proceeds from convertible notes - stockholder	0	0	0	0	155	155
Repayments of convertible notes - stockholder	0	0	0	0	-50	-50
Cash provided by financing activities	5,957	494	1,343	5,603	18,474	24,431
Net increase (decrease) in cash	2,520	-2,980	-3,185	1,859	2,345	4,865
Cash, beginning of period	2,345	5,530	5,530	3,671	0	0
Cash, end of period	$4,865	$2,550	$2,345	$5,530	$2,345	$4,865

BACKGROUND

BACKGROUND	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Nature of Operations [Text Block]	'	'
	NOTE 1 – BACKGROUND	NOTE 1 - BACKGROUND
	GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company” ) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are a development stage pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including prostate, liver, brain and other cancers.    We plan to develop a series of therapies based on our target-activated prodrug technology platform and further test them through Phase I/II clinical trials.	GenSpera, Inc. (“ we”, “us”, “our company “, “our”, “GenSpera” or the “Company” ) was formed under the laws of the State of Delaware in November 2003 and has its principal office in San Antonio, Texas. We are a development stage pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including prostate, liver, brain and other cancers.   We plan to develop a series of therapies based on our target-activated prodrug technology platform and further test them through Phase I/II clinical trials. Our primary focus at the present time is the clinical development of our lead compound, G-202, a novel therapeutic agent with a unique mechanism of action. We have completed enrollment in a Phase Ia/Ib dose-escalation safety, tolerability and dose refinement study in which two patients remain on study as of March 27, 2013. We are also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer).
	Our primary focus at the present time is the clinical development of our lead compound, G-202, a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of G-202, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We are also conducting a Phase II clinical trial of G-202 in patients with liver cancer in which 9 patients have been treated as of November 1, 2013.

MANAGEMENTS_PLANS

MANAGEMENT'S PLANS	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Management Plans to Continue as Going Concern [Abstract]	'	'
Management Plans to Continue as Going Concern Disclosure [Text Block]	'	'
	NOTE 2 – MANAGEMENT’S PLANS	Note 2 - Management’s Plans to Continue as a Going Concern
	Basis of Presentation	Basis of Presentation
	We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included.   We have incurred losses since inception and have a deficit accumulated during the development stage of $ 30.3 million as of September 30, 2013. We anticipate incurring additional losses for the foreseeable future and until such time, if ever, that we can generate significant sales of our therapeutic product candidates currently in development or enter into cash flow positive business development transactions.	The opinion of our independent registered accounting firm on our Financial Statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses since inception and have a deficit accumulated during the development stage of $27.1 million as of December 31, 2012. We anticipate incurring additional losses for the foreseeable future and until such time, if ever, that we can generate significant sales of our therapeutic product candidates currently in development or enter into cash flow positive business development transactions.
	Development Stage Risks	Development Stage Risks
	We are a development stage entity. To date, we have generated no sales revenues, have incurred losses and expect to incur significant additional losses as we advance G-202 through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in research and development of pharmaceutical compounds.	We are a development stage entity. To date, we have generated no sales revenues, have incurred losses and expect to incur significant additional losses as we advance G-202 into Phase II clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in research and development of pharmaceutical compounds.
	Our cash and cash equivalents balance at September 30, 2013 was $ 4.9 million, representing 94% of total assets. Based upon our current expected level of operating expenditures, we expect to able to fund operations for the next twelve to fifteen months. We require additional cash to fund and continue operations beyond that point. This period could be shortened if there are any unanticipated significant increases in planned spending on development programs or other unforeseen events. We need to raise additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that financing will be available when needed to allow us to continue our operations or if available, on terms acceptable to us.	Our cash and cash equivalents balance at December 31, 2012 was $2.3 million, representing 91% of total assets. Based upon our current expected level of operating expenditures, we expect to be able to fund operations through September 2013. We require additional cash to fund and continue operations beyond that point. This period could be shortened if there are any unanticipated significant increases in planned spending on development programs or other unforeseen events. We need to raise additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that other financing will be available when needed to allow us to continue our operations or if available, on terms acceptable to us. We currently have no commitments from any source for future funding.
	In the event financing is not obtained, the Company could pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate development programs, these events could have a material adverse effect on our business, results of operations and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence.	To preserve cash, we have delayed the start of our planned Phase II prostate cancer clinical trial and certain other product development activities. In the event financing is not obtained, the Company could pursue further cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate additional development programs, these events could have a material adverse effect on our business, results of operations and financial condition.
		These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence.

SUMMARY_OF_CRITICAL_ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES

9 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Accounting Policies [Abstract]

'

'

Significant Accounting Policies [Text Block]

'

'

NOTE 3 - SUMMARY OF CRITICAL ACCOUNTING POLICIES

NOTE 3 - Summary of Critical Accounting Policies and Use of Estimates

Use of estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

Research and Development

Research and Development

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, compensation and consulting costs.

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs.

GenSpera incurred research and development expenses of approximately $ 0.6 million for the three months ended September 30, 2013 and 2012, respectively. GenSpera incurred research and development expenses of approximately $ 1.9 million, $ 2.1 million and $ 15.9 million for the nine months ended September 30, 2013 and 2012, and from November 21, 2003 (inception) through September 30, 2013, respectively.

GenSpera incurred research and development expenses of $2.9 million, $3.3 million and $14.0 million for the years ended December 31, 2012 and 2011, and from November 21, 2003 (inception) through December 31, 2012, respectively.

Loss Per Share

Cash Equivalents

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2013 and 2012, as they would be anti-dilutive:

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts.

Nine months ended September 30,

Concentrations of Credit Risk

2013

2012

Shares underlying options outstanding

6,011,023

4,674,628

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $2.3 million and $5.5 million at December 31, 2012 and 2011, respectively.

Shares underlying warrants outstanding

10,266,597

8,357,620

Shares underlying convertible notes outstanding

259,296

250,476

We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including G-202. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company.

16,536,916

13,282,724

Intangible Assets

Fair Value of Financial Instruments

Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Amortization expense recorded during the years ended December 31, 2012 and 2011 was approximately $17,000 for both years. Amortization expense for each one of the next five fiscal years is estimated to be approximately $17,000 in 2013, 2014 and 2015, respectively and approximately $15,000 in 2016, and $12,000 in 2017.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. The Company uses the Black-Scholes option-pricing model to value its warrant derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Office Equipment

Fair Value Measurements

Office equipment is stated at cost less accumulated depreciation.  Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment.

Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

Depreciation expense was approximately $4,000 and $3,000 for the years ended December 31, 2012 and 2011, respectively.

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Loss per Share

Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2012 and 2011, as they would be anti-dilutive:

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of September 30, 2013.   The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

Year Ended December 31,

2013

2012

2011

Balance at beginning of year

$

1,176

Shares underlying options outstanding

4,674,628

3,646,870

Gain on change in fair value of warrant liability

-1,096

Shares underlying warrants outstanding

8,513,984

8,715,289

Reclassification to equity upon exercise of warrants

-80

Shares underlying convertible notes outstanding

252,698

243,854

Balance at end of period

$

-

Fair Value of Financial Instruments

Stock-Based Compensation

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

The Company measures the cost of employee services received in exchange for equity awards based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions, and are valued using option pricing models which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Fair Value Measurements

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Valuation Hierarchy – GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Recent Accounting Pronouncements

The table below summarizes the fair values of our financial liabilities as of December 31, 2012 and 2011 (in thousands):

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company’s present or future financial statements.

Fair Value at

December 31,

Fair Value Measurement Using

2012

Level 1

Level 2

Level 3

Warrant derivative liability

$

1,176

$

—

$

—

$

1,176

Fair Value at

December 31,

Fair Value Measurement Using

2011

Level 1

Level 2

Level 3

Warrant derivative liability

$

1,734

$

—

$

—

$

1,734

The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

2012

2011

Balance at beginning of year

$

1,734

$

2,314

Loss (gain) on change in fair value of warrant liability

50

-580

Reclassification to equity upon exercise of warrants

-608

-

Balance at end of period

$

1,176

$

1,734

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company's present or future financial statements.

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended					12 Months Ended
	Sep. 30, 2013					Dec. 31, 2012
Supplemental Cash Flow Information [Abstract]	'					'
Cash Flow, Supplemental Disclosures [Text Block]	'					'
	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION					NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION
	The following table contains additional information for the periods reported (in thousands):					The following table contains additional information for the periods reported (in thousands).
		Nine months ended September 30,					Year ended December 31,
		2013		2012			2012		2011
	Non-cash financial activities:					Non-cash financial activities:
						Common stock options issued as payment of accrued compensation		674		-
	Common stock options issued as payment of accrued compensation	$	999	$	674	Derivative liability reclassified to equity upon exercise of warrants		608		-
	Derivative liability reclassified to equity upon exercise of warrants		80		427	Common stock units issued as payment of accrued consulting fees		-		60
						Common stock units issued as payment of placement fees		-		110
	There was no cash paid for interest and income taxes for the three or nine months ended September 30, 2013 and 2012.					Common stock and warrants issued as payment of consulting fees		-		499
						There was no cash paid for interest and income taxes for the years ended December 31, 2012 and 2011.

INTELLECTUAL_PROPERTY

INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	NOTE 5 – INTELLECTUAL PROPERTY
	We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders.

ACCRUED_EXPENSES

ACCRUED EXPENSES	9 Months Ended					12 Months Ended
	Sep. 30, 2013					Dec. 31, 2012
Accrued Liabilities, Current [Abstract]	'					'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'					'
	NOTE 5 – ACCRUED EXPENSES					NOTE 6 – ACCRUED EXPENSES
	Accrued expenses consist of the following (in thousands):					Accrued expenses consist of the following (in thousands):
		September 30,		December 31,			December 31,		December 31,
		2013		2012			2012		2011
	Accrued compensation and benefits	$	780	$	958	Accrued compensation and benefits	$	958	$	674
	Accrued research and development		56		100	Accrued research and development		100		-
	Accrued other		205		234	Accrued other		234		54
	Total accrued expenses	$	1,041	$	1,292	Total accrued expenses	$	1,292	$	728

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Notes Payable Disclosure [Abstract]	'	'
Notes Payable Disclosure [Text Block]	'	'
	NOTE 6 – CONVERTIBLE NOTES PAYABLE	NOTE 7 - CONVERTIBLE NOTES PAYABLE
	We have executed convertible notes with our chief executive officer pursuant to which we have borrowed an aggregate of $ 0.2 million, with  $ 0.1 million principal balance outstanding at September 30, 2013. The notes bear an interest rate of 4.2% and matured at various dates through December 6, 2011. Accrued interest at September 30, 2013 and December 31, 2012 was approximately $ 25,000 and  $ 21,000, respectively. As of September 30, 2013, our chief executive officer has not demanded payment of the outstanding principal and accrued interest. Accordingly, we consider these amounts payable on demand.   The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $ 0.50 per share.	We have executed convertible notes with our chief executive officer pursuant to which we have borrowed an aggregate of $0.2 million ($0.1 million principal balance outstanding at December 31, 2012). The notes bear an interest rate of 4.2% and matured at various dates through December 6, 2011. Accrued interest at December 31, 2012 and 2011 was approximately $21,000 and $17,000, respectively. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'
Commitments and Contingencies Disclosure [Text Block]	'	'
	NOTE 7 – COMMITMENTS AND CONTINGENCIES	NOTE 8 - COMMITMENTS AND CONTINGENCIES
	Legal Matters	(a)	Operating Leases
	On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.).   In that complaint, GenSpera, as the licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka (a former doctoral student at Johns Hopkins University) should not be added to either the ‘354 patent or the ‘648 patent as an inventor.   On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent.   Between April 26, 2012 and October 1, 2012, the parties conducted fact discovery.   Between October 1, 2012 and December 1, 2012, the parties conducted limited expert discovery.   On November 1, 2012, Mhaka filed a separate complaint in the State Circuit Court for Baltimore County, Maryland, naming GenSpera as a defendant along with Dr. Samuel Denmeade and Dr. John Isaacs (the named inventors on the ‘354 patent and the ‘648 patent). In the complaint, Mhaka alleged that the defendants are liable under various state law tort theories for omitting her from inventorship on the ‘354 patent and ‘648 patent.   In her prayer for relief, Mhaka sought unspecified damages from the defendants but did not seek to alter the inventorship or ownership of the ‘354 patent or ‘648 patent.   On November 8, 2012, the defendants removed this second action to the United States District Court for the District of Maryland, and on November 16, 2012, the defendants moved to dismiss all claims in the complaint, asserting (among other things) that the claims were preempted by federal patent law.   On January 24, 2013, the Court heard GenSpera’s motion for summary judgment in the original case and the defendants’ motion to dismiss in the second case.   On May 1, 2013, the Court granted GenSpera’s motion for summary judgment in the original case.   In its order, the Court stated that it would proceed to issue a declaratory judgment establishing that Mhaka should not be added to the two patents at issue as an additional inventor pursuant to 35 U.S.C. § 256.”   Reserving any ruling on the issue of whether Mhaka’s state law tort claims are preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint and directed Mhaka to re-file her claims as counterclaims in the original action. On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. On July 16, 2013, the Court issued a scheduling order governing Mhaka’s counterclaims. Under the Court’s schedule, fact discovery is to be completed by December 13, 2013. Expert discovery is to be completed by February 28, 2014.	The Company leases its corporate offices under an operating lease that expires on October 14, 2015.  Rent expense for office space amounted to approximately $27,000 and $19,000 for the years ended December 31, 2012 and 2011, respectively. The following table summarizes future minimum lease payments as of December 31, 2012 (in thousands):
		2013		$	55
		2014			56
		2015			45
		Total minimum lease payments		$	156
		(b)	Employment Agreements
		Effective January 1, 2012, the Company revised the employment agreements with the Chief Executive Officer and Chief Operating Officer. On August 16, 2012, the Company hired the Vice President Finance, Treasurer and Principal Accounting Officer.  On September 2, 2012, the employment agreement with our Chief Operating Officer was automatically extended for an additional year.  The employment agreements contain severance provisions and indemnification clauses.  The indemnification agreement provides for the indemnification and defense of the executive officers, in the event of litigation, to the fullest extent permitted by law.
		As part of the agreements, the executives potentially shall be entitled to the following (in thousands):
				Chief Executive		Chief Operating		Vice President
				Officer		Officer		Finance, Treasurer
								and Principal
								Accounting Officer
		Terminated without cause		$	1,557	$	851	$	294
		Terminated, change of control without good reason			1,557		—		—
		Terminated for cause, death, disability and by executive without good reason			330		289		144

CAPITAL_STOCK_AND_STOCKHOLDERS

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'	'
Stockholders' Equity Note Disclosure [Text Block]	'	'
	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY	NOTE 9 - CAPITAL STOCK AND STOCKHOLDER’S EQUITY
	Common Stock	Common Stock
	During the nine months ended September 30, 2013, 325,670 warrants were exercised into an equivalent number of common shares for which we received proceeds of approximately $ 404,000 , and one million warrants were exercised on a cashless basis into 537,722 common shares. During the nine months ended September 30, 2012, 375,670 options and warrants were exercised into an equivalent number of common shares for which we received proceeds of approximately $ 494,000 , and 78,333 warrants were exercised on a cashless basis into 37,301 common shares.	During the year ended December 31, 2012, 544,639 options and warrants were exercised into an equivalent number of common shares. We received proceeds of $0.7 million from the exercise of the options and warrants. During the year ended December 31, 2012, 78,333 warrants were exercised on a cashless basis into 37,301 common shares.
	Equity Financing	2013 Equity Financing
	August 2013 Offering	See Note 13 - Subsequent Events.
	In August of 2013, we sold an aggregate of $ 5,000,032 , or 3,333,356 units, to accredited and institutional investors. The price per unit was $ 1.50 , with each unit consisting of (i) one share of the Company’s common stock and (ii) one common stock purchase warrant. The warrants have a term of five years and entitle the investors to purchase the Company’s common stock at a price per share of $ 1.75 . In the event that the shares underlying the warrants are not subject to a registration statement at the time of exercise, the warrants may be exercised on a cashless basis after 6 months from the issuance date. The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the warrants contain limitations on the holder’s ability to exercise the warrants in the event such exercise causes the holder to beneficially own in excess of 4.99 % of the Company’s issued and outstanding common stock, subject to a discretionary increase in such limitation by the holder to 9.99 % upon 61 days’ prior notice to the Company.	2012 Equity Financing
	In connection with the offering, we also paid commissions equal to 8 % of gross proceeds, for an aggregate commission of $ 400,003 , and a non-accountable expense allowance equal to 2 % of the gross proceeds, or $ 100,001 to the placement agent. The placement agent also received common stock purchase warrants to purchase such number of shares equal to 8 % of the shares sold in the offering to investors, or 266,668 placement agent warrants with substantially the same terms as the warrants. Additionally, the placement agent was also reimbursed for its legal and due diligence costs in an amount not greater than $ 35,000 . The placement agent also received (i) a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering.	In December of 2012, we offered and sold an aggregate of 296,366 units, in multiple closings, resulting in gross proceeds of approximately $0.7 million (“December Offering”). The price per unit was $2.20. On March 22, 2013, we issued 71,374 additional units in order to adjust the price per unit from $2.20 to $1.773 to be consistent with the price per unit of our March 22, 2013 closing. Each unit consists of: (i) one (1) share of the common stock, par value $0.0001, and (ii) one common stock purchase warrant. The warrants have a term of five years and entitle the holders to purchase common stock at a price per share of $3.00. In the event the shares underlying the warrants are not subject to a registration statement, the warrants may be exercised on a cashless basis after 12 months from the issuance date. The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions, as defined. The warrants do not contain any price protection provisions. Additionally, the warrants contain limitations on the holder’s ability to exercise the warrants in the event such exercise causes the holder to beneficially own in excess of 4.99% of the Company’s issued and outstanding common stock, subject to a discretionary increase in such limitation by the holder to 9.99% upon 61 days’ prior notice to the Company.
	In connection with the offering, investors received certain registration rights. Pursuant to the registration rights, the Company agreed to file a registration statement with the SEC within 45 days from the closing to register the resale of the common shares and common shares underlying the warrants. The Company also agreed to have the registration statement declared effective within 120 days from the filing date. The Company agreed to keep the registration statement continuously effective until the earlier to occur of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act of 1933, as amended. We are also obligated to pay the investors, as partial liquidated damages, a fee of 1.5 % of each investor’s subscription amount per month in cash or shares of the Company’s common stock, at the discretion of the Company, upon the occurrence of certain events, including our failure to file and / or failure to have the registration statement declared effective within the time provided.
		In connection with the offering, we entered into a registration rights agreement with our investors. Pursuant to the registration rights agreements, we agreed to file a “resale” registration statement with the SEC covering all shares of the common stock and the shares underlying the warrants within 45 days of the final closing date of the sale of units and to maintain the effectiveness of the registration statement until all securities have been sold or are otherwise able to be sold pursuant to Rule 144. We have agreed to use our best efforts to have the registration statement declared effective within 90 days of the final closing. We are also obligated to pay to investors, as partial liquidated damages, a fee of 0.50% per month in cash up to a maximum of 6%, upon the occurrence of certain events, including but not limited to failure to file and/or have the registration statement declared effective within the time provided.
	December 2012 Offering
		2011 Equity Financing
	In December of 2012 we commenced a unit offering of our securities.   Each unit consists of: (i) one share of common stock, and (ii) one common stock purchase warrant. The warrants have a term of five years and entitle the holders to purchase common stock at a price per share of $ 3.00. In the event the shares underlying the warrants are not subject to a registration statement, the warrants may be exercised on a cashless basis after 12 months from the issuance date. The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions, as defined. The warrants do not contain any price protection provisions. Additionally, the warrants contain limitations on the holder’s ability to exercise the warrants in the event such exercise causes the holder to beneficially own in excess of 4.99 % of the Company’s issued and outstanding common stock, subject to a discretionary increase in such limitation by the holder to 9.99 % upon 61 days’ prior notice to the Company.
		On January 21, 2011, pursuant to a securities purchase agreement (the Securities Purchase Agreement), we sold 2,074,914 units resulting in gross proceeds to the Company of approximately $3.7 million (Offering).  The price per unit was $1.80.  Each unit consists of: (i) one (1) share of the Company’s common stock, par value $.0001 (Shares), and (ii) one half (1/2) Common Stock Purchase Warrant (Warrant(s)). Of these units, 339,915 were subscribed at December 31, 2010 with gross proceeds to the Company of approximately $0.6 million recorded in the December 31, 2010 financial statements as Common Stock Subscribed.
	In January 2013, we offered and sold an aggregate of 104,095 units in an additional closing resulting in gross proceeds of $ 0.2 million. The price per unit was $ 2.20 . In connection with the December 2012 and January 2013 closings, we issued 96,443 additional units in March 2013 in order to adjust the price per unit from $2.20 to $ 1.773 to be consistent with the price per unit of our March 2013 closing as discussed below.
		The Warrants have a term of five years and entitle the holders to purchase the Company’s common shares at a price per share of $3.30.  In the event the shares underlying the Warrants are not subject to a registration statement, the warrants may be exercised on a cashless basis after 12 months from the issuance date.   The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions.
	In March 2013, we offered and sold an additional 557,256 units in connection with an additional closing, resulting in gross proceeds of $ 1.0 million, at a price per unit of $1.773. In connection with this closing, we incurred placement agent fees and expenses in the amount of $ 37,000 in cash and issued warrants to purchase 18,410 shares at an exercise price per share of $ 3.00 .
		The Warrants do not contain any price protection provisions.   The Warrants are callable by the Company assuming the following: (i) the Common Stock trades above $5.50 for ten (10) consecutive days; (ii) the daily average minimum volume over such ten (10) days is 15,000 or greater; and (iii) there is an effective registration statement covering the underlying shares.   The Securities Purchase Agreement also grants the investors certain piggy-back registration rights.
	In connection with the offering, we agreed to enter into registration rights agreements with our investors. Pursuant to the registration rights agreements, we agreed to file a “resale” registration statement with the SEC covering the shares of common stock included in the units as well as the shares underlying the warrants, within 45 days of the final closing date of the sale of units and to maintain the effectiveness of the registration statement until all securities have been sold or are otherwise able to be sold pursuant to Rule 144. We also agreed to use our best efforts to have the registration statement declared effective within 90 days of the final closing. We are also obligated to pay to investors, as partial liquidated damages, a fee of 0.50 % per month in cash up to a maximum of 6 %, upon the occurrence of certain events, including but not limited to failure to file and/or have the registration statement declared effective within the time provided. Subsequent to the offering, we received a waiver and amendment to the registration rights agreement by holders of a majority of the registrable securities. The effect of the waiver and amendment was to waive all penalties under the registration rights agreement with regard to filing deadlines and effectiveness requirements.	In connection with the Offering, we incurred placement agent and finder’s fees in the amount of $0.1 million in cash and issued warrants to purchase a total of 63,498 shares at an average exercise price per share of $3.26.  Of the fees incurred, $0.1 million was reinvested in the Offering on the same terms and conditions as the investors, resulting in the issuance of 61,498 units.
		On February 16, 2011, pursuant to a securities purchase agreement, we sold an additional 166,691 units resulting in gross proceeds to the Company of $0.3 million. The units contain the same terms as the January 21, 2011 units described above. In connection with the offering, we incurred placement agent and finder’s fees in the amount of approximately $6,000 in cash and issued warrants to purchase a total of 3,558 shares at an exercise price per share of $2.16.
		On April 29, 2011, pursuant to a securities purchase agreement, we sold an additional 1,363,622 units resulting in gross proceeds of $2.2 million.  The price per unit was $1.65.  Each unit consists of: (i) one (1) share of the common stock, par value $.0001, and (ii) one half (1/2) common stock purchase warrant. The warrants have a term of five years and entitle the holders to purchase the common shares at a price per share of $3.15.  In the event the shares underlying the warrants are not subject to a registration statement, the warrants may be exercised on a cashless basis after 12 months from the issuance date.   The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions.  The warrants do not contain any price protection provisions.   The warrants are callable assuming the following: (i) our common stock trades above $6.50 for ten (10) consecutive days; (ii) the daily average minimum volume over such ten (10) days is 15,000 or greater; and (iii) there is an effective registration statement covering the underlying shares.   We also granted the investors certain piggy-back registration rights. In connection with the offering, we incurred finder’s fees in the amount of $60,000 in cash and issued warrants to purchase a total of 36,364 shares at an exercise price per share of $3.15.  The warrants have the same terms and conditions as the investor warrants.
		As a result of the 2011 offerings, the reinvestment of fees, and the issuance of placement agent and finder’s warrants, we issued a total of 3,666,725 shares and 1,936,785 common stock purchase warrants.

STOCK_OPTIONS

STOCK OPTIONS	9 Months Ended											12 Months Ended
	Sep. 30, 2013											Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'											'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'											'
	NOTE 9 – STOCK OPTIONS											NOTE 10 - STOCK OPTIONS
	In March 2013, we amended the terms of our 2009 Executive Compensation Plan (“2009 Plan”) to allow for the issuance of up to 6,000,000 shares of common stock. The terms of our 2007 Equity Compensation Plan (“2007 Plan”) allows for the issuance of up to 6,000,000 shares of common stock. Collectively, the 2009 Plan and 2007 Plan are referred to as “the Plans.”											Deferred Compensation Plan
	Total stock-based compensation expense recognized for stock options and warrants issued using the straight-line method in the statement of operations are as follows:											In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards.
		Three Months Ended September 30,						Nine Months Ended September 30,				GenSpera’s Compensation Plans
		2013			2012			2013		2012
	General and administrative	$	33		$	92		$	729	$	579	The Company’s 2007 Equity Compensation Plan (2007 Plan) and 2009 Executive Compensation Plan (2009 Plan) (together, the Plans) provide for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of GenSpera and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans are administered by a committee of non-employee directors (the Committee). The Committee determines: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award.
	Research and development		13			34			463		452
	Total stock-based compensation	$	46		$	126		$	1,192	$	1,031	As of December 31, 2012, our 2009 Plan authorized up to 1,775,000 shares of common stock to be reserved for issuance upon exercise of stock options or other stock-based awards, and the Company has awarded 1,775,000 stock options, and all such stock options are fully vested. On March 25, 2013, we amended the terms of the 2009 Plan to allow for the issuance of up to 6,000,000 shares of our common stock.
	As of September 30, 2013, there was $57,000 of total unrecognized compensation cost related to non-vested stock options which vest over time. That cost is expected to be recognized over a weighted-average period of approximately six months. As of September 30, 2013, there was no unrecognized compensation expense related to performance-based, non-vested employee stock options. The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the nine months ended September 30, 2013 and 2012:											Our 2007 Plan authorizes up to 1,500,000 shares of common stock to be reserved per year for the issuance of the foregoing awards. Under the 2007 Plan, vesting schedules for stock options vary, but generally vest for a period of not more than five years and at a rate of not less than 20% per year. The maximum term of an option granted under the 2007 Plan is ten years. As of December 31, 2012, 2,873,209 shares of common stock were available for future grants under the Plan.
		September 30,										Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of losses for the year ended December 31, 2012 and 2011 is as follows (in thousands):
		2013				2012
	Volatility		58.7	%			71.6	%					2012		2011
	Expected term (years)		3.9				3.2					Stock-based compensation expense for employees and non-employee directors	$	329	$	624
	Risk-free interest rate		0.7	%			0.5	%				Equity awards for nonemployees issued for services		165		348
	Dividend yield		0	%			0	%				Total stock-based compensation expense	$	494	$	972
	During the nine months ended September 30, 2013, the Company issued options to purchase 1,221,972 and 114,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, the Company issued options to purchase 140,423 shares of common stock to consultants. During the nine month period ended September 30, 2013, no options were exercised. During the nine months ended September 30, 2012, 70,000 options were exercised into an equivalent number of common shares for which we received $35,000 in proceeds. The following is a summary of our stock option activity:											The following table summarizes stock option activity under the Plans:
		Number of			Weighted-			Weighted-average		Aggregate			Number of shares		Weighted-average		Weighted-average		Aggregate intrinsic
		common			average			remaining		intrinsic					exercise price		remaining contractual		value (in thousands)
		shares			exercise			contractual term		value (in							term (in years)
					price			(in years)		thousands)		Outstanding at December 31, 2010		2,612,500	$	1.47
	Outstanding at December 31, 2012		4,674,628		$	1.79						Granted		1,034,370	$	1.94
	Granted		1,476,395		$	2.04						Exercised		—		—
	Forfeited		-140,000		$	2.8						Forfeited		—		—
	Outstanding at September 30, 2013		6,011,023		$	1.83			4.2	$	462	Outstanding at December 31, 2011		3,646,870	$	1.6
	Exercisable at September 30, 2013		5,882,935		$	1.83			4.2	$	462	Granted		1,097,758	$	2.33
												Exercised		-70,000	$	0.5
	Effective June 30, 2013, upon the resignation of the Company’s Vice President of Finance, the Company extended the exercise period for her vested awards from ninety days to the contractual life of the options.  As a result of the modification, the Company recognized incremental compensation cost of approximately $72,000 in the second quarter of 2013.											Forfeited		—		—
												Outstanding at December 31, 2012		4,674,628	$	1.79		4.4	$	2,138
												Exercisable at December 31, 2012		4,477,378	$	1.75		4.3	$	2,138
												As of December 31, 2012, there was $0.1 million of total unrecognized compensation cost related to non-vested stock options which vest over time. That cost is expected to be recognized over a weighted-average period of 0.5 years. As of December 31, 2012, there was $0.1 million of total unrecognized compensation expense related to performance-based, non-vested employee stock options. That cost will be recognized when the performance criteria within the respective performance-based option grants become probable of achievement.
												During 2012 and 2011, the Company issued options to purchase 1,094,658 and 636,370 shares of common stock, respectively, to employees, and non-employee directors under the Plans. The per share weighted-average fair value of the options granted to employees and non-employee directors during 2012 and 2011 was estimated at $0.99 and $0.86, respectively, on the date of grant.
												During 2012 and 2011, the Company issued options to purchase 3,100 and 398,000 shares of common stock, respectively, to consultants under the Plan. The per-share weighted-average fair value of the options granted to consultants during 2012 and 2011 was estimated at $1.27 and $1.31, respectively, on the date of grant.
												The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the years ended December 31, 2012 and 2011:
													Year Ended December 31,
													2012		2011
												Volatility	71.9	%	86	%
												Expected term (years)	2.8		3.3
												Risk-free interest rate	0.3	%	0.6	%
												Dividend yield	None		None
												During the year ended December 31, 2012, 70,000 options were exercised into an equivalent number of common shares. We received proceeds of $35,000 from the exercise of the options.

WARRANTS_AND_DERIVATIVE_WARRAN

WARRANTS AND DERIVATIVE WARRANT LIABILITY	9 Months Ended										12 Months Ended
	Sep. 30, 2013										Dec. 31, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'										'
Derivatives and Fair Value [Text Block]	'										'
	NOTE 10 – WARRANTS AND DERIVATIVE WARRANT LIABILITY										NOTE 11 - WARRANTS AND DERIVATIVE WARRANT LIABILITY
	We account for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price.  We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.										We account for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as derivative liabilities if the stock warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock are at a lower price per share than the then-current warrant exercise price.  We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.
	During the nine months ended September 30, 2013, 325,670 warrants were exercised into an equivalent number of common shares for which we received approximately $ 404,000 in proceeds, and 1,000,000 warrants were exercised on a cashless basis into 537,722 common shares. During the nine months ended September 30, 2012, 305,670 warrants were exercised into an equivalent number of common shares for which we received $ 459,000 in proceeds, and 78,333 warrants were exercised on a cashless basis into 37,301 common shares. The following is a summary of our equity-classified and liability-classified warrant activity:										Transactions involving our equity-classified and liability-classified stock warrants are summarized as follows:
		Number of			Weighted-		Weighted-average		Aggregate			Number of shares			Weighted-average			Weighted-average remaining contractual		Aggregate intrinsic
		shares			average		remaining		intrinsic						exercise price			term (in years)		value (in
					exercise		contractual term		value (in											thousands)
					price		(in years)		thousands)		Outstanding at December 31, 2010		6,311,837		$	2.11
	Outstanding at December 31, 2012		8,513,984		$	2.47					Granted		2,403,452		$	3.13
	Granted		4,376,228		$	1.97					Exercised		—			—
	Exercised		-1,325,670		$	1.06					Forfeited		—			—
	Forfeited		-1,297,945		$	1.5					Outstanding at December 31, 2011		8,715,289		$	2.39
	Outstanding at September 30, 2013		10,266,597		$	2.56		3.1	$	84.1	Granted		314,366		$	2.97
	Exercisable at September 30, 2013		10,266,597		$	2.56		3.1	$	84.1	Exercised		-515,671		$	1.52
											Forfeited		—			—
	The following table summarizes outstanding warrants to purchase common stock as of September 30, 2013:										Outstanding at December 31, 2012		8,513,984		$	2.47			1.9	$	2,792
		Number of			Weighted-		Expiration				Exercisable at December 31, 2012		8,504,984		$	2.47			1.9	$	2,792
		common			average
		shares			exercise						During the year ended December 31, 2012, 515,671 options were exercised into an equivalent number of common shares. We received proceeds of $0.7 million from the exercise of the options.
					price
	Issued to consultants		1,178,759		$	2.27	October 2013 through January 2018				The following table summarizes outstanding warrants to purchase common stock as of December 31, 2012:
	Issued pursuant to 2009 financings		1,455,516		$	3	February 2014 through September 2014					Number of shares		Weighted			Expiration
														Average
	Issued pursuant to 2010 financings		1,022,943		$	3.38	January 2015 through May 2015							Exercise price
											Equity–classified warrants
	Issued pursuant to 2011 financings		1,936,785		$	3.24	January 2016 through April 2016				Issued to consultants	2,262,759		$	1.64		January 2013 through June 2017
											Issued pursuant to 2009 financings	1,455,516		$	3		February 2014 through September 2014
	Issued pursuant to 2012 financings		367,740		$	3	December 2017 through January 2018				Issued pursuant to 2010 financings	1,022,943		$	3.38		January 2015 through May 2015
											Issued pursuant to 2011 financings	1,936,785		$	3.24		January 2016 through April 2016
	Issued pursuant to 2013 financings		4,304,854		$	1.95	December 2017 through August 2018				Issued pursuant to 2012 financings	296,366		$	3		Dec-17
			10,266,597									6,974,369
											Liability–classified warrants
	Equity-classified Warrants										Issued pursuant to July 2008 financings	1,539,615		$	1.5		July 2013 through August 2013
												8,513,984
	Total stock-based compensation recognized for warrants issued to consultants using the straight-line method in the statement of operations for the three months ended September 30, 2013 and 2012 was $ 0 and expense of $ 6,000, respectively. Total stock-based compensation expense recognized for warrants issued to consultants using the straight-line method in the statement of operations for the nine months ended September 30, 2013 and 2012 was $2,000 and $8,000, respectively.
											Equity-classified Warrants
	During the first three months of 2013, in connection with multiple closings of the December 2012 Offering, the Company issued an aggregate of 776,204 common stock purchase warrants, including: 686,420 pursuant to closings in January 2013 and March 2013; 18,410 to the placement agent; and 71,374 additional warrants issued to investors that participated in the December 2012 closing. All warrants were issued with an exercise price of  $ 3.00 per share. In connection with our August 2013 Offering, the Company issued an aggregate of 3,600,024 common stock purchase warrants, including: 3,333,356 issued to investors, and 266,668 to the placement agents. All warrants were issued with an exercise price of $ 1.75 per share.
											During 2012 and 2011, the Company issued warrants to consultants to purchase 18,000 and 466,667 shares of common stock, respectively. The per share weighted-average fair value of the warrants granted to consultants during 2012 and 2011 was estimated at $1.31 and $1.18, respectively, on the date of grant. Total stock-based compensation expense recognized for warrants issued to consultants using the straight-line method in the statement of losses for the year ended December 31, 2012 and 2011 was $14,000 and $851,000, respectively.
	Liability-classified Warrants
											The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the equity-classified warrants issued for services for the years ended December 31, 2012 and 2011:
	The Company has assessed its outstanding equity-linked financial instruments and has concluded that certain of its warrants are subject to derivative accounting as a result of certain anti-dilution provisions contained in the warrants. The fair value of these warrants is classified as a liability in the financial statements with the change in fair value during the periods presented recorded in the statement of operations.  At September 30, 2013, all outstanding liability-classified warrants were either exercised or had expired.
												Year Ended December 31,
	The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:											2012			2011
											Volatility	60.3	%		87	%
			Fair value as of								Expected term (years)	4.7			5
		December 31,									Risk-free interest rate	0.7	%		1.5	%
		2012									Dividend yield	None			None
	Calculated aggregate value (in thousands)	$	1,176								In connection with the December 2012 financing, the Company issued 296,366 common stock purchase warrants at an exercise price of $3.00 per share. As a result of the 2011 offerings, the reinvestment of fees, and the issuance of placement agent and finder’s warrants, we issued a total of 1,936,785 common stock purchase warrants.
	Exercise price per share of warrant	$	1.5
	Closing price per share of common stock	$	2.2								Liability-classified Warrants
	Volatility		54	%
	Expected term (years)		0.5								The Company has assessed its outstanding equity-linked financial instruments and has concluded that certain of its warrants are subject to derivative accounting, as a result of certain anti-dilution provisions contained in the warrants. The fair value of these warrants is classified as a liability in the financial statements with the change in fair value during the periods presented recorded in the statement of operations.
	Risk-free interest rate		0.11	%
	Dividend yield		0	%							The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions (in thousands):
	We have recorded a gain of $ 0.3 million and a loss of $ 0.3 million during the three months ended September 30, 2013 and 2012, respectively, related to the change in fair value of the warrant derivative liability during that period.   We have recorded a gain of $ 1.1 million and a loss of $ 1.0 million during the nine months ended September 30, 2013 and 2012, respectively, related to the change in fair value of the warrant derivative liability during that period.											Fair value as of December 31,
												2012				2011
											Calculated aggregate value	$	1,176			$	1,734
											Exercise price per share of warrant	$	1.5			$	1.5
											Closing price per share of common stock	$	2.2			$	2.01
											Volatility		54	%			71	%
											Expected term (years)		0.5				1.5
											Risk-free interest rate		0.11	%			0.12	%
											Dividend yield		0	%			0	%
											We have recorded loss of $50,000 and gain of $580,000 during the year ended December 31, 2012 and 2011, respectively related to the change in fair value of the warrant derivative liability during that period.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 12 - INCOME TAXES
	Net operating losses for tax purposes of approximately $17.4 million at December 31, 2012 are available for carryover. The net operating losses will expire from 2013 through 2032. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our limited operating history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance increased by $1.8 million and $1.2 million during the years ended December 31, 2012 and 2011, respectively. A reconciliation of the statutory Federal income tax rate and the effective income tax rate for the years ended December 31, 2012 and 2011 follows.
	Significant components of deferred tax assets and liabilities are as follows (in thousands):
		2012			2011
	Deferred tax assets:
	Net operating loss carryover	$	5,914		$	3,873
	Tax credits		114			328
	Valuation allowance		-6,028			-4,201
	Net deferred tax assets	$	-		$	-
	Statutory federal income tax rate		-34	%		-34	%
	State income taxes, net of federal taxes		0	%		0	%
	Non-deductible items		10	%		8	%
	Valuation allowance		24	%		26	%
	Effective income tax rate		0	%		0	%

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 13 – SUBSEQUENT EVENTS
	In January 2013, we offered and sold an aggregate of 104,095 units in an additional closing of our December Offering resulting in gross proceeds of $0.2 million. The price per unit was $2.20. On March 22, 2013, we issued 25,069 additional units in order to adjust the price per unit from $2.20 to $1.773 to be consistent with the price per unit of our March 22, 2013 closing.  All other terms and conditions are the same as the December Offering.
	Between March 22, 2013 and March 27, 2013, we offered and sold 557,256 units in in connection with another closing of our December Offering. This closing resulted in gross proceeds of $1.0 million. The price per unit was $1.773. All other terms and conditions are the same as the December Offering.
	In connection with this closing, we incurred placement agent and finder’s fees and expenses in the amount of $37,000 in cash and issued warrants to purchase 18,410 shares at an exercise price per share of $3.00.

SUMMARY_OF_CRITICAL_ACCOUNTING1

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Accounting Policies [Abstract]

'

'

Use of Estimates, Policy [Policy Text Block]

'

'

Use of estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

Research and Development Expense, Policy [Policy Text Block]

'

'

Research and Development

Research and Development

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, compensation and consulting costs.

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs.

GenSpera incurred research and development expenses of approximately $ 0.6 million for the three months ended September 30, 2013 and 2012, respectively. GenSpera incurred research and development expenses of approximately $ 1.9 million, $ 2.1 million and $ 15.9 million for the nine months ended September 30, 2013 and 2012, and from November 21, 2003 (inception) through September 30, 2013, respectively.

GenSpera incurred research and development expenses of $2.9 million, $3.3 million and $14.0 million for the years ended December 31, 2012 and 2011, and from November 21, 2003 (inception) through December 31, 2012, respectively.

Cash and Cash Equivalents, Policy [Policy Text Block]

'

'

Cash Equivalents

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

'

'

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $2.3 million and $5.5 million at December 31, 2012 and 2011, respectively.

We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including G-202. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company.

Goodwill and Intangible Assets, Policy [Policy Text Block]

'

'

Intangible Assets

Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.

Amortization expense recorded during the years ended December 31, 2012 and 2011 was approximately $17,000 for both years. Amortization expense for each one of the next five fiscal years is estimated to be approximately $17,000 in 2013, 2014 and 2015, respectively and approximately $15,000 in 2016, and $12,000 in 2017.

Property, Plant and Equipment, Policy [Policy Text Block]

'

'

Office Equipment

Office equipment is stated at cost less accumulated depreciation.  Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment.

Depreciation expense was approximately $4,000 and $3,000 for the years ended December 31, 2012 and 2011, respectively.

Earnings Per Share, Policy [Policy Text Block]

'

'

Loss Per Share

Loss per Share

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2013 and 2012, as they would be anti-dilutive:

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2012 and 2011, as they would be anti-dilutive:

Nine months ended September 30,

Year Ended December 31,

2013

2012

2012

2011

Shares underlying options outstanding

6,011,023

4,674,628

Shares underlying options outstanding

4,674,628

3,646,870

Shares underlying warrants outstanding

10,266,597

8,357,620

Shares underlying warrants outstanding

8,513,984

8,715,289

Shares underlying convertible notes outstanding

259,296

250,476

Shares underlying convertible notes outstanding

252,698

243,854

16,536,916

13,282,724

Fair Value of Financial Instruments, Policy [Policy Text Block]

'

'

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. The Company uses the Black-Scholes option-pricing model to value its warrant derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions, and are valued using option pricing models which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.

Fair Value Measurement, Policy [Policy Text Block]

'

'

Fair Value Measurements

Fair Value Measurements

Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

Valuation Hierarchy – GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

The table below summarizes the fair values of our financial liabilities as of December 31, 2012 and 2011 (in thousands):

Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

Fair Value at

December 31,

Fair Value Measurement Using

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of September 30, 2013.   The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

2012

Level 1

Level 2

Level 3

2013

Warrant derivative liability

$

1,176

$

—

$

—

$

1,176

Balance at beginning of year

$

1,176

Gain on change in fair value of warrant liability

-1,096

Fair Value at

Reclassification to equity upon exercise of warrants

-80

December 31,

Fair Value Measurement Using

Balance at end of period

$

-

2011

Level 1

Level 2

Level 3

Warrant derivative liability

$

1,734

$

—

$

—

$

1,734

The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

2012

2011

Balance at beginning of year

$

1,734

$

2,314

Loss (gain) on change in fair value of warrant liability

50

-580

Reclassification to equity upon exercise of warrants

-608

-

Balance at end of period

$

1,176

$

1,734

Income Tax, Policy [Policy Text Block]

'

'

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

'

'

Stock-Based Compensation

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for equity awards based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.

New Accounting Pronouncements, Policy [Policy Text Block]

'

'

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company’s present or future financial statements.

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company's present or future financial statements.

SUMMARY_OF_CRITICAL_ACCOUNTING2

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Tables)	9 Months Ended					12 Months Ended
	Sep. 30, 2013					Dec. 31, 2012
Accounting Policies [Abstract]	'					'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'					'
	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2013 and 2012, as they would be anti-dilutive:					The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2012 and 2011, as they would be anti-dilutive:
		Nine months ended September 30,					Year Ended December 31,
		2013		2012			2012		2011
	Shares underlying options outstanding		6,011,023		4,674,628	Shares underlying options outstanding		4,674,628		3,646,870
	Shares underlying warrants outstanding		10,266,597		8,357,620	Shares underlying warrants outstanding		8,513,984		8,715,289
	Shares underlying convertible notes outstanding		259,296		250,476	Shares underlying convertible notes outstanding		252,698		243,854
			16,536,916		13,282,724
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'					'
						The table below summarizes the fair values of our financial liabilities as of December 31, 2012 and 2011 (in thousands):
							Fair Value at
							December 31,		Fair Value Measurement Using
							2012		Level 1		Level 2		Level 3
						Warrant derivative liability	$	1,176	$	—	$	—	$	1,176
							Fair Value at
							December 31,		Fair Value Measurement Using
							2011		Level 1		Level 2		Level 3
						Warrant derivative liability	$	1,734	$	—	$	—	$	1,734
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]	'					'
	The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):					The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):
		2013					2012		2011
	Balance at beginning of year	$	1,176			Balance at beginning of year	$	1,734	$	2,314
	Gain on change in fair value of warrant liability		-1,096			Loss (gain) on change in fair value of warrant liability		50		-580
	Reclassification to equity upon exercise of warrants		-80			Reclassification to equity upon exercise of warrants		-608		-
	Balance at end of period	$	-			Balance at end of period	$	1,176	$	1,734

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended					12 Months Ended
	Sep. 30, 2013					Dec. 31, 2012
Supplemental Cash Flow Information [Abstract]	'					'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'					'
	The following table contains additional information for the periods reported (in thousands):					The following table contains additional information for the periods reported (in thousands).
		Nine months ended September 30,					Year ended December 31,
		2013		2012			2012		2011
	Non-cash financial activities:					Non-cash financial activities:
						Common stock options issued as payment of accrued compensation		674		-
	Common stock options issued as payment of accrued compensation	$	999	$	674	Derivative liability reclassified to equity upon exercise of warrants		608		-
	Derivative liability reclassified to equity upon exercise of warrants		80		427	Common stock units issued as payment of accrued consulting fees		-		60
						Common stock units issued as payment of placement fees		-		110
						Common stock and warrants issued as payment of consulting fees		-		499

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	9 Months Ended					12 Months Ended
	Sep. 30, 2013					Dec. 31, 2012
Accrued Liabilities, Current [Abstract]	'					'
Schedule of Accrued Liabilities [Table Text Block]	'					'
	Accrued expenses consist of the following (in thousands):					Accrued expenses consist of the following (in thousands):
		September 30,		December 31,			December 31,		December 31,
		2013		2012			2012		2011
	Accrued compensation and benefits	$	780	$	958	Accrued compensation and benefits	$	958	$	674
	Accrued research and development		56		100	Accrued research and development		100		-
	Accrued other		205		234	Accrued other		234		54
	Total accrued expenses	$	1,041	$	1,292	Total accrued expenses	$	1,292	$	728

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The following table summarizes future minimum lease payments as of December 31, 2012 (in thousands):
	2013	$	55
	2014		56
	2015		45
	Total minimum lease payments	$	156
Restructuring and Related Costs [Table Text Block]	'
	As part of the agreements, the executives potentially shall be entitled to the following (in thousands):
		Chief Executive		Chief Operating		Vice President
		Officer		Officer		Finance, Treasurer
						and Principal
						Accounting Officer
	Terminated without cause	$	1,557	$	851	$	294
	Terminated, change of control without good reason		1,557		—		—
	Terminated for cause, death, disability and by executive without good reason		330		289		144

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	9 Months Ended											12 Months Ended
	Sep. 30, 2013											Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'											'
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	'											'
												Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of losses for the year ended December 31, 2012 and 2011 is as follows (in thousands):
													2012		2011
												Stock-based compensation expense for employees and non-employee directors	$	329	$	624
												Equity awards for nonemployees issued for services		165		348
												Total stock-based compensation expense	$	494	$	972
Schedule Of Stock Based Compensation Expenses For Stock Options And Warrants Issued [Table Text Block]	'											'
	Total stock-based compensation expense recognized for stock options and warrants issued using the straight-line method in the statement of operations are as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013		2012
	General and administrative	$	33		$	92		$	729	$	579
	Research and development		13			34			463		452
	Total stock-based compensation	$	46		$	126		$	1,192	$	1,031
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'											'
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the nine months ended September 30, 2013 and 2012:											The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the years ended December 31, 2012 and 2011:
		September 30,											Year Ended December 31,
		2013				2012							2012		2011
	Volatility		58.7	%			71.6	%				Volatility	71.9	%	86	%
	Expected term (years)		3.9				3.2					Expected term (years)	2.8		3.3
	Risk-free interest rate		0.7	%			0.5	%				Risk-free interest rate	0.3	%	0.6	%
	Dividend yield		0	%			0	%				Dividend yield	None		None
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'											'
	The following is a summary of our stock option activity:											The following table summarizes stock option activity under the Plans:
		Number of			Weighted-			Weighted-average		Aggregate			Number of shares		Weighted-average		Weighted-average		Aggregate intrinsic
		common			average			remaining		intrinsic					exercise price		remaining contractual		value (in thousands)
		shares			exercise			contractual term		value (in							term (in years)
					price			(in years)		thousands)		Outstanding at December 31, 2010		2,612,500	$	1.47
	Outstanding at December 31, 2012		4,674,628		$	1.79						Granted		1,034,370	$	1.94
	Granted		1,476,395		$	2.04						Exercised		—		—
	Forfeited		-140,000		$	2.8						Forfeited		—		—
	Outstanding at September 30, 2013		6,011,023		$	1.83			4.2	$	462	Outstanding at December 31, 2011		3,646,870	$	1.6
	Exercisable at September 30, 2013		5,882,935		$	1.83			4.2	$	462	Granted		1,097,758	$	2.33
												Exercised		-70,000	$	0.5
												Forfeited		—		—
												Outstanding at December 31, 2012		4,674,628	$	1.79		4.4	$	2,138
												Exercisable at December 31, 2012		4,477,378	$	1.75		4.3	$	2,138

WARRANTS_AND_DERIVATIVE_WARRAN1

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Tables)	9 Months Ended										12 Months Ended
	Sep. 30, 2013										Dec. 31, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'										'
Schedule of Share-based Compensation, Activity [Table Text Block]	'										'
	The following is a summary of our equity-classified and liability-classified warrant activity:										Transactions involving our equity-classified and liability-classified stock warrants are summarized as follows:
		Number of			Weighted-		Weighted-average		Aggregate			Number of shares			Weighted-average			Weighted-average remaining contractual		Aggregate intrinsic
		shares			average		remaining		intrinsic						exercise price			term (in years)		value (in
					exercise		contractual term		value (in											thousands)
					price		(in years)		thousands)		Outstanding at December 31, 2010		6,311,837		$	2.11
	Outstanding at December 31, 2012		8,513,984		$	2.47					Granted		2,403,452		$	3.13
	Granted		4,376,228		$	1.97					Exercised		—			—
	Exercised		-1,325,670		$	1.06					Forfeited		—			—
	Forfeited		-1,297,945		$	1.5					Outstanding at December 31, 2011		8,715,289		$	2.39
	Outstanding at September 30, 2013		10,266,597		$	2.56		3.1	$	84.1	Granted		314,366		$	2.97
	Exercisable at September 30, 2013		10,266,597		$	2.56		3.1	$	84.1	Exercised		-515,671		$	1.52
											Forfeited		—			—
											Outstanding at December 31, 2012		8,513,984		$	2.47			1.9	$	2,792
											Exercisable at December 31, 2012		8,504,984		$	2.47			1.9	$	2,792
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	'										'
	The following table summarizes outstanding warrants to purchase common stock as of September 30, 2013:										The following table summarizes outstanding warrants to purchase common stock as of December 31, 2012:
		Number of			Weighted-		Expiration					Number of shares		Weighted			Expiration
		common			average									Average
		shares			exercise									Exercise price
					price						Equity–classified warrants
	Issued to consultants		1,178,759		$	2.27	October 2013 through January 2018				Issued to consultants	2,262,759		$	1.64		January 2013 through June 2017
											Issued pursuant to 2009 financings	1,455,516		$	3		February 2014 through September 2014
	Issued pursuant to 2009 financings		1,455,516		$	3	February 2014 through September 2014				Issued pursuant to 2010 financings	1,022,943		$	3.38		January 2015 through May 2015
											Issued pursuant to 2011 financings	1,936,785		$	3.24		January 2016 through April 2016
	Issued pursuant to 2010 financings		1,022,943		$	3.38	January 2015 through May 2015				Issued pursuant to 2012 financings	296,366		$	3		Dec-17
												6,974,369
	Issued pursuant to 2011 financings		1,936,785		$	3.24	January 2016 through April 2016				Liability–classified warrants
											Issued pursuant to July 2008 financings	1,539,615		$	1.5		July 2013 through August 2013
	Issued pursuant to 2012 financings		367,740		$	3	December 2017 through January 2018					8,513,984
	Issued pursuant to 2013 financings		4,304,854		$	1.95	December 2017 through August 2018
			10,266,597
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]	'										'
											The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the equity-classified warrants issued for services for the years ended December 31, 2012 and 2011:
												Year Ended December 31,
												2012			2011
											Volatility	60.3	%		87	%
											Expected term (years)	4.7			5
											Risk-free interest rate	0.7	%		1.5	%
											Dividend yield	None			None
Schedule of Share-based Payment Award, Warrants Derivative Liability Valuation Assumptions [Table Text Block]	'										'
	The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:										The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions (in thousands):
			Fair value as of									Fair value as of December 31,
		December 31,										2012				2011
		2012
											Calculated aggregate value	$	1,176			$	1,734
	Calculated aggregate value (in thousands)	$	1,176								Exercise price per share of warrant	$	1.5			$	1.5
	Exercise price per share of warrant	$	1.5								Closing price per share of common stock	$	2.2			$	2.01
	Closing price per share of common stock	$	2.2								Volatility		54	%			71	%
	Volatility		54	%							Expected term (years)		0.5				1.5
	Expected term (years)		0.5								Risk-free interest rate		0.11	%			0.12	%
	Risk-free interest rate		0.11	%							Dividend yield		0	%			0	%
	Dividend yield		0	%

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of deferred tax assets and liabilities are as follows (in thousands):
		2012			2011
	Deferred tax assets:
	Net operating loss carryover	$	5,914		$	3,873
	Tax credits		114			328
	Valuation allowance		-6,028			-4,201
	Net deferred tax assets	$	-		$	-
	Statutory federal income tax rate		-34	%		-34	%
	State income taxes, net of federal taxes		0	%		0	%
	Non-deductible items		10	%		8	%
	Valuation allowance		24	%		26	%
	Effective income tax rate		0	%		0	%

MANAGEMENTS_PLANS_Details_Text

MANAGEMENT'S PLANS (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010	Nov. 20, 2003
In Thousands, unless otherwise specified
Deficit accumulated during the development stage	$30,329	$27,083	'	$20,163	'	'
Cash and Cash Equivalents, at Carrying Value	$4,865	$2,345	$2,550	$5,530	$3,671	$0
Percentage of Cash and Cash Equivalents in Total Assets	94.00%	91.00%	'	'	'	'

SUMMARY_OF_CRITICAL_ACCOUNTING3

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Shares underlying, outstanding	16,536,916	13,282,724	'	'
Employee Stock Option [Member]	'	'	'	'
Shares underlying, outstanding	6,011,023	4,674,628	4,674,628	3,646,870
Warrant [Member]	'	'	'	'
Shares underlying, outstanding	10,266,597	8,357,620	8,513,984	8,715,289
Convertible Notes Payable [Member]	'	'	'	'
Shares underlying, outstanding	259,296	250,476	252,698	243,854

SUMMARY_OF_CRITICAL_ACCOUNTING4

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Warrant derivative liability	$0	$1,176	$1,734	$2,314
Fair Value, Inputs, Level 1 [Member]	'	'	'	'
Warrant derivative liability	'	0	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'	'
Warrant derivative liability	'	0	0	'
Fair Value, Inputs, Level 3 [Member]	'	'	'	'
Warrant derivative liability	'	$1,176	$1,734	'

SUMMARY_OF_CRITICAL_ACCOUNTING5

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Details 2) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		109 Months Ended	118 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013
Balance at beginning of year	'	'	$1,176	$1,734	$1,734	$2,314	'	'
Loss (gain) on change in fair value of warrant liability	-330	281	-1,096	1,029	50	-580	1,010	-86
Reclassification to equity upon exercise of warrants	'	'	-80	'	-608	0	'	'
Balance at end of period	$0	'	$0	'	$1,176	$1,734	$1,176	$0

SUMMARY_OF_CRITICAL_ACCOUNTING6

SUMMARY OF CRITICAL ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		109 Months Ended	118 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2010	Nov. 20, 2003
Research and Development Expense, Total	$571	$600	$1,907	$2,127	$2,922	$3,302	$13,979	$15,886	'	'
Cash and Cash Equivalents	4,865	2,550	4,865	2,550	2,345	5,530	2,345	4,865	3,671	0
Amortization	'	'	'	'	17,000	17,000	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	'	'	'	'	17,000	'	17,000	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	'	'	'	'	17,000	'	17,000	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	'	'	'	'	17,000	'	17,000	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	'	'	'	'	15,000	'	15,000	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	'	'	'	'	12,000	'	12,000	'	'	'
Depreciation	'	'	'	'	$4,000	$3,000	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'12 years	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'3 years	'	'	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'17 years	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'5 years	'	'	'	'	'

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Non-cash financial activities:	'	'	'	'	'
Common stock options issued as payment of accrued compensation	$999	$674	$674	$0	'
Derivative liability reclassified to equity upon exercise of warrants	80	427	608	0	86
Common stock units issued as payment of accrued consulting fees	'	'	0	60	'
Common stock units issued as payment of placement fees	'	'	0	110	'
Common stock and warrants issued as payment of consulting fees	'	'	$0	$499	'

INTELLECTUAL_PROPERTY_Details_

INTELLECTUAL PROPERTY (Details Textual) (USD $)	9 Months Ended		12 Months Ended		48 Months Ended	109 Months Ended	118 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013
Payments To Acquire Intangible Assets	$0	$0	$0	$0	$212	$194	$194

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Accrued compensation and benefits	$780	$958	$674
Accrued research and development	56	100	0
Accrued other	205	234	54
Total accrued expenses	$1,041	$1,292	$728

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) (Chief Executive Officer [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Chief Executive Officer [Member]	'	'	'
Convertible Notes Payable, Total	$200,000	$200,000	'
Long-term Debt, Gross	100,000	100,000	'
Debt Instrument, Interest Rate, Effective Percentage	4.20%	4.20%	'
Debt Instrument, Maturity Date	6-Dec-11	6-Dec-11	'
Interest Payable	$25,000	$21,000	$17,000
Debt Instrument, Convertible, Conversion Price	$0.50	$0.50	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2012
In Thousands, unless otherwise specified
2013	$55
2014	56
2015	45
Total minimum lease payments	$156

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Terminated without Cause [Member] | Chief Executive Officer [Member]	'
Severance Provision And Indemnification Charges	$1,557
Terminated without Cause [Member] | Chief Operating Officer [Member]	'
Severance Provision And Indemnification Charges	851
Terminated without Cause [Member] | Vice President Finance, Treasurer and Principal Accounting Officer [Member]	'
Severance Provision And Indemnification Charges	294
Terminated Change of Control without Good Reason [Member] | Chief Executive Officer [Member]	'
Severance Provision And Indemnification Charges	1,557
Terminated Change of Control without Good Reason [Member] | Chief Operating Officer [Member]	'
Severance Provision And Indemnification Charges	0
Terminated Change of Control without Good Reason [Member] | Vice President Finance, Treasurer and Principal Accounting Officer [Member]	'
Severance Provision And Indemnification Charges	0
Terminated for Cause Death Disability and by Executive with Good Reason [Member] | Chief Executive Officer [Member]	'
Severance Provision And Indemnification Charges	330
Terminated for Cause Death Disability and by Executive with Good Reason [Member] | Chief Operating Officer [Member]	'
Severance Provision And Indemnification Charges	289
Terminated for Cause Death Disability and by Executive with Good Reason [Member] | Vice President Finance, Treasurer and Principal Accounting Officer [Member]	'
Severance Provision And Indemnification Charges	$144

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Operating Leases, Rent Expense	$27,000	$19,000
Lease Expiration Date	14-Oct-15	'

CAPITAL_STOCK_AND_STOCKHOLDERS1

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) (USD $)

9 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2007

Jan. 21, 2011

Feb. 16, 2011

Apr. 29, 2011

Dec. 31, 2011

Dec. 31, 2010

Mar. 31, 2013

Jan. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Aug. 31, 2013

Securities Purchase Agreement1 [Member]

Securities Purchase Agreement2 [Member]

Securities Purchase Agreement3 [Member]

Securities Purchase Agreement3 [Member]

Securities Purchase Agreement6[Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

Equity Financing 2012 [Member]

August 2013 Offering [Member]

March 22 2013 [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

March 22 2013 [Member]

March 22 2013 [Member]

Warrants Exercised

325,670

305,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

$404,000

$459,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options And Warrants Exercised

'

375,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Options and Warrant Exercises

'

494,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,032

Warrants Exercised on Cashless Basis

1,000,000

78,333

78,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Stock Options and Warrant Exercised

'

'

544,639

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued During Period Upon Exercise of Warrants

537,722

37,301

37,301

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

296,366

71,374

'

'

'

3,333,356

Stock Issued During Period, Value, New Issues

'

'

'

'

650,000

'

'

'

'

'

'

'

700,000

'

'

'

'

'

Stock Issued During Period New Issues Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

$2.20

'

'

$2.20

$1.77

$1.50

Stock Issued During Period, Shares, Stock Options and Warrant Issued

'

'

'

'

'

2,074,914

166,691

1,363,622

'

339,915

557,256

104,095

'

'

'

'

'

'

Proceeds from Issuance Common Stock and Warrants

'

'

'

'

'

3,700,000

300,000

2,200,000

'

600,000

1,000,000

200,000

'

'

'

'

'

'

Stock Issued During Period, Price Per Share Stock Options and Warrant

'

'

'

'

'

$1.80

'

$1.65

'

'

$1.77

$2.20

'

'

'

'

'

'

Placement Agent and Finders Fees Incurred

'

'

'

'

'

100,000

6,000

60,000

'

'

37,000

'

'

'

'

'

'

'

Common Stock Purchase Warrants Issued Shares (in shares)

'

'

'

1,936,785

'

'

'

'

1,936,785

'

18,410

'

'

'

'

'

'

'

Stock Issued During Period Shares Adjust Price Per Unit

'

'

'

'

'

'

'

'

'

'

96,443

'

'

'

'

'

'

'

Stock Units Components, Description

'

'

'

'

'

'Each unit consists of: (i) one (1) share of the Companys common stock, par value $.0001 (Shares), and (ii) one half (1/2) Common Stock Purchase Warrant (Warrant(s)).

'

'Each unit consists of: (i) one (1) share of the common stock, par value $.0001, and (ii) one half (1/2) common stock purchase warrant.

'

'

'

'adjust the price per unit from $2.20 to $1.773

'Each unit consists of: (i) one (1) share of common stock, par value $0.0001, and (ii) one common stock purchase warrant.

'

'

'

'

'each unit consisting of (i) one share of the Companys common stock and (ii) one common stock purchase warrant.

Class of Warrant or Right, Exercise Price of Warrants

'

'

'

'

'

$3.26

$2.16

'

'

'

$3

'

$3

'

'

'

'

$1.75

Warrants Expiration Period

'

'

'

'

'

'5 years

'

'5 years

'

'

'

'

'5 years

'

'

'

'

'5 years

Beneficially Interest, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

4.99%

Discretionary Increase, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

9.99%

'

'

'

'

9.99%

Partial Liquidated Damages Fee, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

6.00%

'

'

1.50%

Common Stock Shares Exercise Price

'

'

'

'

'

$3.30

'

$3.15

'

'

'

'

'

'

'

'

'

'

Warrants Callable Assumptions Description

'

'

'

'

'

'The Warrants are callable by the Company assuming the following: (i) the Common Stock trades above $5.50 for ten (10) consecutive days; (ii) the daily average minimum volume over such ten (10) days is 15,000 or greater; and (iii) there is an effective registration statement covering the underlying shares.

'

'The warrants are callable assuming the following: (i) our common stock trades above $6.50 for ten (10) consecutive days; (ii) the daily average minimum volume over such ten (10) days is 15,000 or greater; and (iii) there is an effective registration statement covering the underlying shares.

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

63,498

3,558

36,364

'

'

'

'

'

'

'

'

'

'

Reinvested Amount In Offering

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance Of Common Stock and Warrants Shares

'

'

'

'

'

61,498

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Common Shares Issued

'

'

'

'

'

'

'

'

3,666,725

'

'

'

'

'

'

'

'

'

Commission Percentage On Gross Proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

Payments for Commissions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,003

Non Accountable Expense Allowance Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

Non Accountable Expense To Placement Agent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,001

Warrant Percentage To Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

Warrants To Purchase Of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

266,668

Legal And Due Diligence Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$35,000

Additional Placement Agent Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering.

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
General and administrative	$33	$92	$729	$579
Research and development	13	34	463	452
Total stock-based compensation	$46	$126	$1,192	$1,031

STOCK_OPTIONS_Details_1

STOCK OPTIONS (Details 1)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Volatility	58.70%	71.60%	71.90%	86.00%
Expected term (years)	'3 years 10 months 24 days	'3 years 2 months 12 days	'2 years 9 months 18 days	'3 years 3 months 18 days
Risk-free interest rate	0.70%	0.50%	0.30%	0.60%
Dividend yield	0.00%	0.00%	'	'

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Number of shares, Outstanding, Beginning balance (in shares)	4,674,628	3,646,870	3,646,870	2,612,500
Number of shares, Granted (in shares)	1,476,395	'	1,097,758	1,034,370
Number of shares, Exercised (in shares)	'	-70,000	-70,000	0
Number of shares, Forfeited (in shares)	-140,000	'	0	0
Number of shares, Outstanding, Ending balance (in shares)	6,011,023	'	4,674,628	3,646,870
Number of shares, Exercisable (in shares)	5,882,935	'	4,477,378	'
Weighted average exercise price, Outstanding at beginning of the period (in dollars per share)	$1.79	$1.60	$1.60	$1.47
Weighted Average Exercise Price, Granted (in dollars per share)	$2.04	'	$2.33	$1.94
Weighted Average Exercise Price, Exercised (in dollars per share)	'	'	$0.50	$0
Weighted Average Exercise Price, Forfeited (in dollars per share)	$2.80	'	$0	$0
Weighted Average Exercise Price, Outstanding at end of the period (in dollars per share)	$1.83	'	$1.79	$1.60
Weighted Average Exercise Price, Exercisable (in dollars per share)	$1.83	'	$1.75	'
Weighted Average Remaining Contractual Term, Outstanding	'4 years 2 months 12 days	'	'4 years 4 months 24 days	'
Weighted Average Remaining Contractual Term, Exercisable	'4 years 2 months 12 days	'	'4 years 3 months 18 days	'
Aggregate intrinsic value, Outstanding (in dollars)	$462	'	$2,138,000	'
Aggregate intrinsic value, Exercisable (in dollars)	$462	'	$2,138,000	'

STOCK_OPTIONS_Details_3

STOCK OPTIONS (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Stock-based compensation expense for employees and non-employee directors	$329	$624
Equity awards for nonemployees issued for services	165	348
Total stock-based compensation expense	$494	$972

STOCK_OPTIONS_Details_Textual

STOCK OPTIONS (Details Textual) (USD $)	3 Months Ended	9 Months Ended		12 Months Ended					12 Months Ended
	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Mar. 31, 2013
						Performance-Based Non-Vested Employee Stock Options [Member]	Plan 2009 [Member]	Plan 2009 [Member]	Plan 2009 [Member]	Plan 2007 [Member]	Plan 2007 [Member]
									March 25, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	'	'	6,000,000	1,775,000	'	1,500,000	6,000,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	'	'	'	$100,000	'	$57,000	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	72,000	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement, Options, Issued to Employees	'	1,221,972	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement, Options, Issued to Non Employee Directors	'	114,000	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement, Options, Issued to Consultants	'	140,423	'	3,100	398,000	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	'	70,000	70,000	0	'	'	'	'	'	'
Proceeds from Stock Options Exercised	'	'	$35,000	$35,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	'	'	'	1,775,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	'	'	'	'	'	'	6,000,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	2,873,209	'	'	'	'	'	'	'
Employee Service Share-based Compensation Non Vested Awards, Weighted Average Period for Total Compensation Cost to be Recognized	'	'	'	'6 months	'	'	'	'	'	'	'
Share-based Compensation Arrangement Options Issued to Employees and Non Employee Directors	'	'	'	1,094,658	636,370	'	'	'	'	'	'
Share-based Compensation Arrangement Options Issued to Employees and Non Employee Directors, Weighted Average Price	'	'	'	$0.99	$0.86	'	'	'	'	'	'
Share-based Compensation Arrangement Options Issued to Consultants, Weighted Average Price	'	'	'	$1.27	$1.31	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Vesting Rate Minimum	'	'	'	'	'	'	'	'	'	'not less than 20% per year.	'
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Description	'	'	'	'period of not more than five years	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Assumptions, Expected Term	'	'	'	'10 years	'	'	'	'	'	'	'

WARRANTS_AND_DERIVATIVE_WARRAN2

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Number of shares, Outstanding at beginning of period (in shares)	8,513,984	8,715,289	6,311,837
Number of shares, Granted (in shares)	4,376,228	314,366	2,403,452
Number of shares, Exercised (in shares)	-1,325,670	-515,671	0
Number of shares, Forfeited (in shares)	-1,297,945	0	0
Number of shares, Outstanding at ending of period (in shares)	10,266,597	8,513,984	8,715,289
Number of shares, Exercisable at end of period (in shares)	10,266,597	8,504,984	'
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$2.47	$2.39	$2.11
Weighted-average exercise price, Granted (in dollars per share)	$1.97	$2.97	$3.13
Weighted-average exercise price, Exercised (in dollars per share)	$1.06	$1.52	$0
Weighted-average exercise price, Forfeited (in dollars per share)	$1.50	$0	$0
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$2.56	$2.47	$2.39
Weighted-average exercise price, Exercisable at end of period (in dollars per share)	$2.56	$2.47	'
Weighted-average remaining contractual term, Outstanding at end of period	'3 years 1 month 6 days	'1 year 10 months 24 days	'
Weighted-average remaining contractual term, Exercisable at end of period	'3 years 1 month 6 days	'1 year 10 months 24 days	'
Aggregate intrinsic value, Outstanding at end of period (in dollars)	$84,100	$2,792,000	'
Aggregate intrinsic value, Exercisable at end of period (in dollars)	$84,100	$2,792,000	'

WARRANTS_AND_DERIVATIVE_WARRAN3

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 1) (USD $)

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Consultant [Member]

Financing 2009 [Member]

Financing 2010 [Member]

Financing 2011 [Member]

Financing 2012 [Member]

Financing 2013 [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Liability Classified Warrants [Member]

Liability Classified Warrants [Member]

Consultant [Member]

Financing 2009 [Member]

Financing 2010 [Member]

Financing 2011 [Member]

Financing 2012 [Member]

Financing 2008 [Member]

Number of shares (in shares)

10,266,597

1,178,759

1,455,516

1,022,943

1,936,785

367,740

4,304,854

6,974,369

2,262,759

1,455,516

1,022,943

1,936,785

296,366

8,513,984

1,539,615

Weighted Average Exercise price (in dollars per share)

'

$2.27

$3

$3.38

$3.24

$3

$1.95

'

$1.64

$3

$3.38

$3.24

$3

'

$1.50

Expiration

'

'October 2013 through January 2018

'February 2014 through September 2014

'January 2015 through May 2015

'January 2016 through April 2016

'December 2017 through January 2018

'December 2017 through August 2018

'

'January 2013 through June 2017

'February 2014 through September 2014

'January 2015 through May 2015

'January 2016 through April 2016

'December 2017

'

'July 2013 through August 2013

WARRANTS_AND_DERIVATIVE_WARRAN4

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 2) (Equity Classified Warrants [Member])	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Equity Classified Warrants [Member]	'	'
Volatility	60.30%	87.00%
Expected term (years)	'4 years 8 months 12 days	'5 years
Risk-free interest rate	0.70%	1.50%
Dividend yield	0.00%	0.00%

WARRANTS_AND_DERIVATIVE_WARRAN5

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 3) (Liability Classified Warrants [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Liability Classified Warrants [Member]	'	'
Calculated aggregate value (in thousands)	$1,176	$1,734
Exercise price per share of warrant	$1.50	$1.50
Closing price per share of common stock	$2.20	$2.01
Volatility	54.00%	71.00%
Expected term (years)	'6 months	'1 year 6 months
Risk-free interest rate	0.11%	0.12%
Dividend yield	0.00%	0.00%

WARRANTS_AND_DERIVATIVE_WARRAN6

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details Textual) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Aug. 31, 2013

Mar. 31, 2013

Jan. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Financing December 2012 [Member]

Equity Classified Warrants [Member]

Warrants Exercised

'

'

325,670

305,670

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

$404,000

$459,000

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised on Cashless Basis

'

'

1,000,000

78,333

78,333

'

'

'

'

'

'

'

'

'

'

Shares Issued During Period Upon Exercise of Warrants

'

'

537,722

37,301

37,301

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Expense Recognized for Warrants Issued to Consultants

'

'

'

'

14,000

851,000

'

'

'

0

6,000

2,000

8,000

'

'

Common Stock Purchase Warrants Issued Shares

'

'

'

'

'

1,936,785

3,600,024

686,420

776,204

'

'

'

'

'

'

Share-based Compensation Arrangement, Warrants Issued to Placement Agent

'

'

'

'

'

'

266,668

'

'

'

'

'

'

18,410

'

Share-based Compensation Arrangement, Warrants Issued to Investors

'

'

'

'

'

'

3,333,356

'

'

'

'

'

'

71,374

'

Warrants Weighted Average Fair Value

'

'

'

'

$1.31

$1.18

$1.75

'

'

'

'

'

'

$3

'

Derivative, Gain on Derivative

300,000

'

1,100,000

'

'

580,000

'

'

'

'

'

'

'

'

'

Derivative, Loss on Derivative

'

300,000

'

1,000,000

50,000

'

'

'

'

'

'

'

'

'

'

Proceeds From Options and Warrant Exercises

'

'

'

$494,000

$700,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement Warrants Issued to Consultants (in shares)

'

'

'

'

18,000

466,667

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding (in shares)

10,266,597

'

10,266,597

'

'

'

'

'

'

'

'

'

'

6,974,369

296,366

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:	'	'
Net operating loss carryover	$5,914	$3,873
Tax credits	114	328
Valuation allowance	-6,028	-4,201
Net deferred tax assets	$0	$0
Statutory federal income tax rate	-34.00%	-34.00%
State income taxes, net of federal taxes	0.00%	0.00%
Non-deductible items	10.00%	8.00%
Valuation allowance	24.00%	26.00%
Effective income tax rate	0.00%	0.00%

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Operating Loss Carryforwards	$17.40	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	$1.80	$1.20
Operating Loss Carry forwards Valuation Allowance Percentage	100.00%	'
Operating Loss Carryforward Expiration Dates	'expire from 2013 through 2032	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2007	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
		January 31, 2013 [Member]	March 22 2013 [Member]	March 22 2013 [Member]	March 22 2013 [Member]	Between March 22, 2013 and March 27, 2013 [Member]
				Minimum [Member]	Maximum [Member]
Common stock issued (in shares)	'	104,095	25,069	'	'	557,256
Common stock issued	$650,000	$200,000	'	'	'	$1,000,000
Stock Issued During Period New Issues, Price Per Share	'	$2.20	'	$1.77	$2.20	$1.77
Placement Agent and Finders Fees Incurred	'	'	'	'	'	$37,000
Share-based Compensation Arrangement, Warrants Issued to Placement Agent	'	'	'	'	'	18,410
Warrant or Right Exercise Price of Warrants or Rights	'	'	'	'	'	$3